Solasia Pharma K.K
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial d… Read more
Solasia Pharma K.K (9SO) - Total Liabilities
Latest total liabilities as of June 2025: €588.00 Million EUR
Based on the latest financial reports, Solasia Pharma K.K (9SO) has total liabilities worth €588.00 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Solasia Pharma K.K - Total Liabilities Trend (2016–2024)
This chart illustrates how Solasia Pharma K.K's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Solasia Pharma K.K Competitors by Total Liabilities
The table below lists competitors of Solasia Pharma K.K ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cardlytics Inc
NASDAQ:CDLX
|
USA | $297.51 Million |
|
Lotus Bakeries NV
PINK:LOTBY
|
USA | $676.63 Million |
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
Poland | zł1.03 Billion |
|
ANGLE plc
OTCQX:ANPCF
|
USA | $6.39 Million |
|
Mithril Silver and Gold Ltd
AU:MTH
|
Australia | AU$2.06 Million |
|
Kpx Green Chem
KO:083420
|
Korea | ₩80.47 Billion |
|
Fosterville South Exploration Ltd
OTCQX:FSXLF
|
USA | $3.06 Million |
|
U.S. GoldMining Inc. Common stock
NASDAQ:USGO
|
USA | $860.81K |
Liability Composition Analysis (2016–2024)
This chart breaks down Solasia Pharma K.K's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Solasia Pharma K.K's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Solasia Pharma K.K (2016–2024)
The table below shows the annual total liabilities of Solasia Pharma K.K from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €206.00 Million | -41.81% |
| 2023-12-31 | €354.00 Million | -25.00% |
| 2022-12-31 | €472.00 Million | -15.26% |
| 2021-12-31 | €557.00 Million | -73.76% |
| 2020-12-31 | €2.12 Billion | +106.32% |
| 2019-12-31 | €1.03 Billion | +60.53% |
| 2018-12-31 | €641.00 Million | +43.55% |
| 2017-12-31 | €446.54 Million | +64.45% |
| 2016-12-31 | €271.53 Million | -- |